1H-Indole-5-carbonyl chloride, 1-methyl- | 949899-71-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1H-Indole-5-carbonyl chloride, 1-methyl-
• 英文别名: 1-methylindole-5-carbonyl chloride
• CAS: 949899-71-2
• 化学式: C₁₀H₈ClNO
• 分子量: 193.633
• InChiKey: PEFVZDZPYGMCPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1H-Indole-5-carbonyl chloride, 1-methyl- 、 2,6-二氟-3-胺基吡啶 在 吡啶 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.67h， 生成 5-fluoro-2-(1-methyl-1H-indol-5-yl)oxazolo[5,4-b]pyridine
  参考文献：
  名称：

  Synthesis and Evaluation of 5-Fluoro-2-aryloxazolo[5,4-b]pyridines as β-Amyloid PET Ligands and Identification of MK-3328

  摘要：

  5-Fluoro-2-aryloxazolo[5,4-b]pyridines were synthesized and investigated as potential F-18 containing beta-amyloid PET ligands. In competition binding assays using human AD brain homogenates, compounds 14b, 16b, and 17b were identified as having favorable potency versus human beta-amyloid plaque and were radiolabeled for further evaluation in in vitro binding and in vivo PET imaging experiments. These studies led to the identification of 17b (MK-3328) as a candidate PET ligand for the clinical assessment of beta-amyloid plaque load.

  DOI：

  10.1021/ml200018n
• 作为产物：
  描述：

  1-甲基-1H-吲哚-5-甲酸 在 2,4,6-三氯苯甲酰氯 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 1H-Indole-5-carbonyl chloride, 1-methyl-
  参考文献：
  名称：

  Pyrrolobenzodiazepine carboxyamide vasopressin agonists

  摘要：

  本发明提供了以下结构的化合物： 其中： X、Y和Z分别选自O、S、CH、CH2、N或NR4； W是从(CH2)n选择的基团； n=1-2； R1、R2分别独立地为氢、直链烷基（C1-C6）、支链烷基（C3-C7）、环烷基（C3-C7）、烷氧基烷基（C2-C7）、卤素、直链或支链烷氧基（C1-C6）、羟基、CF3或全氟烷基（C2-C6）； R3为氢或直链烷基（C1-C6）、支链烷基（C3-C7）、环烷基（C3-C7）、烷氧基烷基（C2-C7）或羟基烷基（C1-C6）； R4选自氢或（较低烷基（C1-C6））；和 R5选自卤素或氢； 或其药学上可接受的盐：以及利用这些化合物治疗可能通过抗利尿素活性得到缓解或减轻的疾病的方法和药物组合物，包括尿崩症、夜尿症、夜尿、尿失禁、出血和凝血障碍或暂时延迟排尿。

  公开号：

  US06344451B1

文献信息

• Pyrrolobenzodiazepine carboxyamide vasopressin agonists
  申请人：American Home Products

  公开号：US06344451B1

  公开（公告）日：2002-02-05

  The present invention provides compounds of the formula: wherein: X, Y and Z are independently selected from O, S, CH, CH2, N, or NR4; W is moiety selected from (CH2)n; n=1-2; R1, R2 are independently, hydrogen, straight chain alkyl (C1-C6), branched chain alkyl (C3-C7), cycloalkyl (C3-C7), alkoxyalkyl (C2-C7), halogen, straight or branched chain alkoxy (C1-C6), hydroxy, CF3, or perfluoroalkyl (C2-C6); R3 is hydrogen or a straight chain alkyl group (C1-C6), branched chain alkyl (C3-C7), cycloalkyl (C3-C7), alkoxyalkyl (C2-C7), or hydroxyalkyl (C1-C6); R4 is selected from hydrogen, or (lower alkyl (C1-C6); and R5 is selected from halogen or hydrogen; or a pharmaceutically acceptable salt thereof: as well as methods and pharmaceutical compositions utilizing these compounds for the treatment of disorder which may be remedied or alleviated by vasopressin agonist activity, including diabetes insipidus, nocturnal enuresis, nocturia, urinary incontinence, bleeding and coagulation disorders, or temporary delay of urination.

  本发明提供了以下结构的化合物： 其中： X、Y和Z分别选自O、S、CH、CH2、N或NR4； W是从(CH2)n选择的基团； n=1-2； R1、R2分别独立地为氢、直链烷基（C1-C6）、支链烷基（C3-C7）、环烷基（C3-C7）、烷氧基烷基（C2-C7）、卤素、直链或支链烷氧基（C1-C6）、羟基、CF3或全氟烷基（C2-C6）； R3为氢或直链烷基（C1-C6）、支链烷基（C3-C7）、环烷基（C3-C7）、烷氧基烷基（C2-C7）或羟基烷基（C1-C6）； R4选自氢或（较低烷基（C1-C6））；和 R5选自卤素或氢； 或其药学上可接受的盐：以及利用这些化合物治疗可能通过抗利尿素活性得到缓解或减轻的疾病的方法和药物组合物，包括尿崩症、夜尿症、夜尿、尿失禁、出血和凝血障碍或暂时延迟排尿。
• BENZOPYRROLIDONE DERIVATIVES POSSESSING ANTIVIRAL AND ANTICANCER PROPERTIES
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP3056202A1

  公开（公告）日：2016-08-17

  The present invention relates to benzopyrrolidone derivatives and/or pharmaceutically acceptable salts thereof for the use in the treatment of infectious diseases or cancer, and pharmaceutical compositions containing at least one of said benzopyrrolidone derivatives and/or pharmaceutically acceptable salts thereof for the use in the treatment of infectious diseases or cancer.

  本发明涉及苯并吡咯烷酮衍生物和/或其药用可接受盐，用于治疗传染病或癌症，并包含至少一种所述苯并吡咯烷酮衍生物和/或其药用可接受盐的药物组合物，用于治疗传染病或癌症。
• Paired Oxidative and Reductive Catalysis: Breaking the Potential Barrier of Electrochemical C(sp³)−H Alkenylation**
  作者：Long Zou、Xiaofan Wang、Siqi Xiang、Weipeng Zheng、Qingquan Lu

  DOI：10.1002/anie.202301026

  日期：2023.6.12

  Due to the intrinsic inertness of alkanes, strong oxidative conditions are typically required to enable their C(sp³)−H functionalization. Herein, a paired electrocatalysis strategy was developed by integrating oxidative catalysis with reductive catalysis in one cell without interference, in which earth‐abundant iron and nickel are employed as the anodic and cathodic catalysts, respectively. This approach lowers the previously high oxidation potential required for alkane activation, enabling electrochemical alkane functionalization at the ultra‐low oxidation potential of ≈0.25 V vs. Ag/AgCl under mild conditions. Structurally diverse alkenes, including challenging all‐carbon tetrasubstituted olefins, can be accessed using readily available alkenyl electrophiles.

  摘要由于烷烃的内在惰性，通常需要在强氧化条件下才能实现其 C(sp3)-H 功能化。在此，我们开发了一种成对电催化策略，将氧化催化与还原催化无干扰地集成在一个电池中，其中采用了富含地球的铁和镍分别作为阳极和阴极催化剂。这种方法降低了以往烷烃活化所需的高氧化电位，在温和的条件下，以相对于 Ag/AgCl ≈0.25 V 的超低氧化电位实现了电化学烷烃官能化。利用容易获得的烯基亲电体，可以获得结构多样的烯烃，包括具有挑战性的全碳四取代烯烃。
• Synthesis and SAR of p38α MAP kinase inhibitors based on heterobicyclic scaffolds
  作者：T.G. Murali Dhar、Stephen T. Wrobleski、Shuqun Lin、Joseph A. Furch、David S. Nirschl、Yi Fan、Gordon Todderud、Sidney Pitt、Arthur M. Doweyko、John S. Sack、Arvind Mathur、Murray McKinnon、Joel C. Barrish、John H. Dodd、Gary L. Schieven、Katerina Leftheris

  DOI：10.1016/j.bmcl.2007.07.029

  日期：2007.9

  The synthesis and structure-activity relationships (SAR) of p38 alpha MAP kinase inhibitors based on heterobicyclic scaffolds are described. This effort led to the identification of compound (21) as a potent inhibitor of p38a MAP kinase with good cellular potency toward the inhibition of TNF-alpha production. X-ray co-crystallography of an oxalamide analog (24) bound to unphosphorylated p38 alpha is also disclosed. (c) 2007 Elsevier Ltd. All rights reserved.
• [EN] BENZOPYRROLIDONE DERIVATIVES POSSESSING ANTIVIRAL AND ANTICANCER PROPERTIES<br/>[FR] DÉRIVÉS DE BENZOPYRROLIDONE POSSÉDANT DES PROPRIÉTÉS ANTIVIRALES ET ANTICANCÉREUSES
  申请人：MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V

  公开号：WO2016131789A1

  公开（公告）日：2016-08-25

  The present invention relates to benzopyrrolidone derivatives and/or pharmaceutically acceptable salts thereof for the use in the treatment of infectious diseases or cancer, and pharmaceutical compositions containing at least one of said benzopyrrolidone derivatives and/or pharmaceutically acceptable salts thereof for the use in the treatment of infectious diseases or cancer.